[1]
|
陈梅, 廖蕴华. 原发性IgA肾病流行病学进展[J]. 医学研究杂志, 2007, 36(11): 24-26.
|
[2]
|
Xu, X., Ning, Y., Shang, W.F., Li, M.L., Ku, M., Li, Q., et al. (2016) Analysis of 4931 Renal Biopsy Data in Central China from 1994 to 2014. Renal Failure, 38, 1021-1030. https://doi.org/10.1080/0886022X.2016.1183443
|
[3]
|
杜夕雯, 肖敦明, 敖超群, 张岩磊, 宣建伟. 中国IgA肾病成人疾病负担[J]. 中国药物经济学, 2022, 17(7): 46-52.
|
[4]
|
Rosselli, J.L., Thacker, S.M., Karpinski, J.P. and Petkewicz, K.A. (2011) Treatment of IgA Nephropathy: An Update. Annals of Pharmacotherapy, 45, 1284-1296. https://doi.org/10.1345/aph.1Q122
|
[5]
|
薛海, 张士勇. 来氟米特在免疫性疾病中的应用进展[J]. 安徽医药, 2009, 13(7): 723-726.
|
[6]
|
张爱平, 张磊, 王艳侠, 丁尧海, 张颖玮, 郭治, 石书梅, 陈海英. 来氟米特治疗IgA肾病64例[J]. 中华肾脏病杂志, 2004, 20(3): 176.
|
[7]
|
张婕, 刘光陵. 来氟米特治疗IgA肾病的Meta分析[J]. 医学研究生学报, 2010, 23(9): 950-955.
https://doi.org/10.16571/j.cnki.1008-8199.2010.09.015
|
[8]
|
Rückemann, K., Fairbanks, L.D., Carrey, E.A., et al. (1998) Leflunomide Inhibits Pyrimidine de Novo Synthesis in Mitogen-Stimulated T-Lymphocytes from Healthy Humans. Journal of Biological Chemistry, 273, 21682-21691.
https://doi.org/10.1074/jbc.273.34.21682
|
[9]
|
Han, S., Yao, T., Lu, Y., Chen, M., Xu, Y. and Wang, Y. (2021) Efficacy and Safety of Immunosuppressive Monotherapy Agents for IgA Nephropathy: A Network Meta-Analysis. Frontiers in Pharmacology, 11, Article ID: 539545.
https://doi.org/10.3389/fphar.2020.539545
|
[10]
|
Yi, J., He, Z., Xu, S. and Feng, S. (2019) Efficacy and Safety of Leflunomide in IgA Nephropathy: A Systematic Review and Meta-Analysis. International Urology and Nephrology, 51, 1987-1998.
https://doi.org/10.1007/s11255-019-02255-6
|
[11]
|
Wu, J., Duan, S.W., Sun, X.F., Li, W.G., Wang, Y.P., Liu, W.H., Zhang, J.R., Lun, L.D., et al. (2016) Efficacy of Leflunomide, Telmisartan, and Clopidogrel for Immunoglobulin A Nephropathy: A Randomized Controlled Trial. Chinese Medical Journal, 129, 1894-1903. https://doi.org/10.4103/0366-6999.187848
|
[12]
|
Chen, S., Yin, Q., Ren, S., et al. (2018) A Comparison of the Effectiveness of Cyclophosphamide, Leflunomide, Corticosteroids, or Conservative Management Alone in Patients with IgA Nephropathy: A Retrospective Observational Study]. Scientific Reports, 8, Article No. 13662. https://doi.org/10.1038/s41598-018-31727-5
|
[13]
|
Lou, T.Q., Wang, C., Chen, Z.J., Shi, C.G., Tang, H., Liu, X., Yin, P.D. and Yu, X.Q. (2006) Randomised Controlled Trial of Leflunomide in the Treatment of Immunoglobulin A Nephropathy. Nephrology (Carlton, Vic.), 11, 113-116.
https://doi.org/10.1111/j.1440-1797.2006.00547.x
|
[14]
|
赵晓华, 刘宝环, 张炜, 等. 来氟米特联合激素治疗伴肾小管间质损害的IgA肾病临床疗效观察[J]. 影像研究与医学应用, 2017, 1(11): 224-226.
|
[15]
|
刘晓渭, 王汉民, 陈威, 等. 来氟米特与霉酚酸酯治疗表现为肾病综合征的IgA肾病的疗效比较[J]. 实用医学杂志, 2007, 23(9): 1378-1379.
|
[16]
|
张杰, 何俊, 李正良, 等. 来氟米特治疗IgA肾病的临床研究[J]. 中国实用内科杂志, 2005, 25(7): 628-630.
|
[17]
|
Ni, Z.H., Zhang, Z., Yu, Z.Z., Lu, F.M., Mei, C.L., et al. (2021) Leflunomide plus Low-Dose Prednisone in Patients with Progressive IgA Nephropathy: A Multicenter, Prospective, Randomized, Open-Labeled, and Controlled Trial. Renal Failure, 43, 1214-1221. https://doi.org/10.1080/0886022X.2021.1963775
|
[18]
|
Li, Y., Xiong, Y., Huang, T., et al. (2021) Clinical Efficacy and Safety of Full-Dose versus Half-Dose Corticosteroids plus Leflunomide for IgA Nephropathy. BMC Nephrology, 22, Article No. 364.
https://doi.org/10.1186/s12882-021-02555-z
|
[19]
|
Beaman, J.M., Hackett, L.P., Luxton, G., et al. (2002) Effect of Hemodialysis on Leflunomide Plasma Concentrations. Annals of Pharmacotherapy, 36, 75-77. https://doi.org/10.1345/aph.1A127
|
[20]
|
王志宏, 傅得兴, 封宇飞. 来氟米特的不良反应及合理应用[J]. 中国全科医学, 2008, 11(6): 496-498.
|
[21]
|
王晔, 杨婷, 王路路, 张海霞. 羟氯喹在IgA肾病中的临床研究进展[J]. 中南药学, 2021, 19(11): 2371-2376.
|
[22]
|
Taylor, P., et al. (2022) Cytokines and Production of Aberrantly O-Glycosylated IgA1, the Main Autoantigen in IgA Nephropathy. Journal of Interferon & Cytokine Research: The Official Journal of the International Society for Interferon and Cytokine Research, 42, 301-315. https://doi.org/10.1089/jir.2022.0039
|
[23]
|
Marie-Bénédicte, L.S., et al. (2021) Is Complement the Main Accomplice in IgA Nephropathy? From Initial Observations to Potential Complement-Targeted Therapies. Molecular Immunology, 140, 1-11.
https://doi.org/10.1016/j.molimm.2021.09.010
|
[24]
|
Anna, L., et al. (2022) The Role of Dendrin in IgA Nephropathy. Nephrology, Dialysis, Transplantation, gfac208.
|
[25]
|
Xiao, Z., Wang, B.B. and Li, S.F. (2019) Role of Dendrtic Cells in IgA Nephropathy Pathogenesis. American Journal of BioScience, 7, 50-57. https://doi.org/10.11648/j.ajbio.20190702.14
|
[26]
|
林洁珊, 胡文学, 郝文科, 余枫, 刘伟, 吴燕华, 梁馨苓. IgA肾病患者肾组织树突状细胞和M2巨噬细胞的数目与分布与临床病理的相关性[J]. 中华肾脏病杂志, 2019(11): 809-815.
|
[27]
|
Yang, Y.C., Fu, H., Zhang, B. and Wu, Y.B. (2022) Interleukin-6 Downregulates the Expression of Vascular Endothelial-Cadherin and Increases Permeability in Renal Glomerular Endothelial Cells via the Trans-Signaling Pathway. Inflammation. https://doi.org/10.1007/s10753-022-01711-3
|
[28]
|
Miret-Casals, L., et al. (2018) Identification of New Activators of Mitochondrial Fusion Reveals a Link between Mitochondrial Morphology and Pyrimidine Metabolism. Cell Chemical Biology, 25, 268-278.e4.
https://doi.org/10.1016/j.chembiol.2017.12.001
|
[29]
|
Intachai, K., Chattipakorn, S., Chattipakorn, N. and Shinlapawittayatorn, K. (2021) Acetylcholine Receptor Agonists Exert Cytoprotection against Hypoxia/Reoxygenation Injurythrough Inhibiting Apoptosis and Promoting Mitochondrial Dynamics and Biogenesis. Biophysical Journal, 120, 29a. https://doi.org/10.1016/j.bpj.2020.11.2073
|
[30]
|
Stojić-Vukanić, Z., et al. (2011) Differentiation and Function of Human Monocyte-Derived Dendritic Cells under the Influence of Leflunomide. Archives of Biological Sciences, 63, 353-364. https://doi.org/10.2298/ABS1102353S
|
[31]
|
Kirsch, B.M., et al. (2005) The Active Metabolite of Leflunomide, A77 1726, Interferes with Dendritic Cell Function. Arthritis Research & Therapy, 7, R694-R703.
|
[32]
|
Tang, Y., et al. (2008) Study on Protective Effects and Its Mechanism of Leflunomide on Renal Tissue in Rat IgA Nephropathy Model. Chinese Critical Care Medicine, 20, 283-285.
|
[33]
|
Pei, S.W. and Li, Y. (2021) Huangkui Capsule in Combination with Leflunomide Improves Immunoglobulin a Nephropathy by Inhibiting the TGF-β1/Smad3 Signaling Pathway. Clinics (Sao Paulo, Brazil), 76, e2904.
https://doi.org/10.6061/clinics/2021/e2904
|
[34]
|
Hamilton, L.C., Vojnovic, I. and Warner, T.D. (1999) A771726, the Active Metabolite of Leflunomide, Directly Inhibits the Activity of Cyclo-Oxygenase-2 in Vitro and in Vivo in a Substrate-Sensitive Manner. British Journal of Pharmacology, 127, 1589-1596. https://doi.org/10.1038/sj.bjp.0702708
|
[35]
|
Savikko, J., Von Willebrand, E. and Häyry, P. (2003) Leflunomide Analogue FK778 Is Vasculoprotective Independent of Its Immunosuppressive Effect: Potential Applications for Restenosis and Chronic Rejection. Transplantation, 76, 455-458. https://doi.org/10.1097/01.TP.0000076382.87978.73
|
[36]
|
徐炳侠, 李明红, 武文斌. 来氟米特对IgA肾病肾小球电荷屏障损伤的干预[J]. 中国保健, 2007, 15(12): 84-85.
|
[37]
|
董丽群, 王峥. 硫酸乙酰肝素与肾小球疾病研究进展[J]. 国际泌尿系统杂志, 2008, 28(6): 837-840.
|
[38]
|
潘锡正, 林芳. 肾小球电荷屏障研究的新进展[J]. 医学综述, 2014, 20(12): 2138-2140.
|
[39]
|
姚宏伟, 金涌, 李常玉, 汤晓林, 张运芳, 李俊. 来氟米特人体耐受性实验研究[J]. 安徽医药, 2001(2): 93-95.
|
[40]
|
Maddison, P., Kiely, P., Kirkham, B., et al. (2005) Leflunomide in Rheumatoid Arthritis: Recommendations through a Process of Consensus. Rheumatology (Oxford), 44, 280-286. https://doi.org/10.1093/rheumatology/keh500
|
[41]
|
Prakash, A. and Jarvis, B. (1999) Leflunomide: A Review of Its Use in Active Rheumatoid Arthritis. Drugs, 58, 1137-1164. https://doi.org/10.2165/00003495-199958060-00010
|
[42]
|
Rozman, B. (2002) Clinical Pharmacokinetics of Leflunomide. Clinical Pharmacokinetics, 41, 421-430.
https://doi.org/10.2165/00003088-200241060-00003
|
[43]
|
Sammaritano, L.R., Bermas, B.L., Chakravarty, E.E., Chambers, C., Clowse, M.E.B., Lockshin, M.D., et al (2020) 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Care & Research, 72, 461-488. https://doi.org/10.1002/acr.24130
|
[44]
|
Chan, V., Charles, B.G. and Tett, S.E. (2005) Population Pharmacokinetics and Association between A77 1726 Plasma Concentrations and Disease Activity Measures Following Administration of Leflunomide to People with Rheumatoid Arthritis. British Journal of Clinical Pharmacology, 60, 257-264. https://doi.org/10.1111/j.1365-2125.2005.02415.x
|
[45]
|
张翠锋, 吴敏, 谢海棠. 来氟米特药物代谢酶和转运体的基因组学研究进展[J]. 中国医院药学杂志, 2019, 39(5): 535-538. https://doi.org/10.13286/j.cnki.chinhosppharmacyj.2019.05.23
|
[46]
|
Kim, K.-A., Joo, H.-J. and Park, J.-Y. (2011) Effect of ABCG2 Genotypes on the Pharmacokinetics of A771726, an Active Metabolite of Prodrug Leflunomide, and Association of A771726 Exposure with Serum Uric Acid Level. European Journal of Clinical Pharmacology, 67, 129-134. https://doi.org/10.1007/s00228-010-0916-0
|
[47]
|
Hopkins, A.M., et al. (2014) Individualization of Leflunomide Dosing in Rheumatoid Arthritis Patients. Personalized Medicine, 11, 449-461. https://doi.org/10.2217/pme.14.23
|